Abstract:For many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of dugs developed as "glucose-lowering agents," SGLT2 inhibitors and GLP-1 receptor agonists, can reduce macrovascular and renal complications. These studies have prompted debate about the main aim of type 2 diabetes management. In this review, three eras of diabetes management are described according to the treatment recommendations, such as the ADA/EASD consensus, moving from a pure glucocentric view into the present cardio-renal outcome-oriented approach, this has been endorsed by major diabetes and cardiology societies. While in the first era normalizing HbA1c was the only focus (e.g., UK Prospective Diabetes Study), failing to show a reduction in cardiovascular morbidity and mortality, further studies analyzing the pros and cons of intensified control such as ACCORD, VADT, ADVANCE recognized that treatment intensification was associated with weight gain and hypoglycemia, thereby potentially reducing the benefits of glycemic control. Therefore, the focus in the second area was on controlling HbA1c without these unwanted effects. The consistent beneficial results of several cardiovascular outcome trials with SGLT2 inhibitors and GLP-1 receptor agonists showing significantly improved cardio-renal outcomes, induced a paradigm shift: a change from (only) control of HbA1c to an organ-protective approach with the main focus now on cardio-renal risk; this is now considered as the third era. Recent data indicating beneficial effects of glucose-lowering agents in particular SGLT2 inhibitors even in subjects without diabetes, improving hospitalization for heart failure and renal outcomes might reveal another new era, which could then be considered a fourth era. While current international guidelines call for this paradigm shift, registry data show that we are still far from translating this objective into real-world practice.

Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus

Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus

Diabetes insipidus: vasopressin deficiency...

Vasopressin deficiency: a hypothesized driver of both social impairment and fluid imbalance in autism spectrum disorder

International Guidelines for the Diagnosis and Management of Hyperinsulinism

Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency

International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance)

Diabetes Insipidus: Diagnosis, Pathogenesis, and Management

Challenging case of hypernatraemia in infancy

A Missense Mutation in the Arginine‐vasopressin Neurophysin‐ii Gene Causes Autosomal Dominant Neurohypophyseal Diabetes Insipidus in a Chinese Family

Diagnosis and differential diagnosis of diabetes insipidus: Update

Redefining Diagnostic Cut‐Offs for the Indirect Water Deprivation Test

Renaming Diabetes Types

Nomenclature in Nephrology: Preserving 'renal' and 'nephro' in the Glossary of Kidney Health and Disease.

Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care

The Ulaanbaatar agreement: Revising diabetes terminology in Asia to combat stigma

Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?

Forty-One Individuals With Mutations in the AVP-NPII Gene Associated With Familial Neurohypophyseal Diabetes Insipidus

Language matters. Addressing the use of language in the care of people with diabetes: position statement of the English Advisory Group

[Diabetic nephropathy and cardiovascular risk]

Maturity‐onset diabetes of the young: A proposal for updated nomenclature